0 rating

Treatment Strategies

Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing–remitting multiple sclerosis.

Kalincik T, Jokubaitis V, Izquierdo G et al.

Royal Melbourne Hospital, Parkville, VIC, Australia.

 Mult Scler 2015;21:1159–71.

Melinda Magyari’s review: Observational studies comparing disease-modifying treatments (DMTs) in the treatment of relapsing–remitting multiple sclerosis (MS) in real-world settings have made an important contribution to the body of evidence supporting the efficacy and safety of DMTs that was established by randomized clinical trials. Head-to-head comparisons of DMTs are few, and the four currently approved injectable medications are considered comparable to each other in terms of the efficacy measures of relapse rate and disability progression in clinical practice.

Return to top


The Role of B Cells in Multiple Sclerosis: Experimental and Clinical Aspects
Til Menge, MD, Gerd Meyer zu Hörste, MD, and Bernd C Kieseier, MD
CML Multiple Sclerosis
Pharmacogenomics in Multiple Sclerosis
Manuel Comabella, MD and Xavier Montalban, MD
CML Multiple Sclerosis
The Role of MRI as a Predictive Marker for Disease Progression Measured by the Expanded Disability Status Scale
Antonia Ceccarelli, MD, Domenico Caputo, MD, and Marco Rovaris, MD
CML Multiple Sclerosis
Advances in Multiple Sclerosis Therapy: New Oral Disease-Modifying Agents
Andreas Lutterotti, MD and Thomas Berger, MD, MSc
CML Multiple Sclerosis
Optical Coherence Tomography as a Marker of Axonal Damage in Multiple Sclerosis
Shiv Saidha, MRCPI, Christopher Eckstein, MD, and John N Ratchford, MD
CML Multiple Sclerosis